Clene Inc. (CLNN) 10% owner entity reports 3 stock sales in January 2026

Q: How many Clene (CLNN) shares were sold in each reported transaction?

Symbiosis II, LLC sold 26,105 shares on January 13, 2026 at $4.89 per share, 19,621 shares on January 14, 2026 at $5.12 per share, and 12,563 shares on January 15, 2026 at $5.10 per share.

Q: Is the CLNN insider ownership direct or indirect in this Form 4?

The ownership is reported as indirect , with the nature of ownership described as "By Symbiosis II, LLC" for all the listed common stock transactions.

Q: Who is the reporting person in this Clene (CLNN) Form 4?

The reporting person is Ugwumba Chidozie , identified as a 10% owner of Clene Inc., with the reported transactions carried out through Symbiosis II, LLC.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Clene Inc. reported insider activity by a 10% owner. An entity identified as Symbiosis II, LLC, associated with reporting person Ugwumba Chidozie, sold Clene common stock over three days in January 2026. The sales were 26,105 shares on January 13, 2026 at $4.89 per share, 19,621 shares on January 14, 2026 at $5.12 per share, and 12,563 shares on January 15, 2026 at $5.10 per share. After these transactions, Symbiosis II, LLC was reported to indirectly hold 650,298 Clene common shares.

Insider Trade Summary

Net Seller: 58,289 shares

Net Sell 3 txns

Insider Ugwumba Chidozie

Role 10% Owner

Sold 58,289 shs ($292K)

Type	Security	Shares	Price	Value
Sale	Common Stock	12,563	$5.10	$64K
Sale	Common Stock	19,621	$5.12	$100K
Sale	Common Stock	26,105	$4.89	$128K

Holdings After Transaction: Common Stock — 650,298 shares (Indirect, By Symbiosis II, LLC)

Footnotes (1)

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 01/16/2026 - 11:16 AM

FAQ

What insider transactions did CLNN report on this Form 4?

The filing reports that Symbiosis II, LLC, an entity associated with a 10% owner of Clene Inc. (CLNN), sold common stock on three dates in January 2026, with each sale reported as an open-market sale coded "S".

How many Clene (CLNN) shares were sold in each reported transaction?

Symbiosis II, LLC sold 26,105 shares on January 13, 2026 at $4.89 per share, 19,621 shares on January 14, 2026 at $5.12 per share, and 12,563 shares on January 15, 2026 at $5.10 per share.

How many CLNN shares does the reporting entity hold after these sales?

Following the reported January 2026 transactions, Symbiosis II, LLC is shown as indirectly holding 650,298 shares of Clene common stock.

Is the CLNN insider ownership direct or indirect in this Form 4?

The ownership is reported as indirect, with the nature of ownership described as "By Symbiosis II, LLC" for all the listed common stock transactions.

Who is the reporting person in this Clene (CLNN) Form 4?

The reporting person is Ugwumba Chidozie, identified as a 10% owner of Clene Inc., with the reported transactions carried out through Symbiosis II, LLC.

Were any derivative securities for CLNN reported in this Form 4?

The section for derivative securities is present but shows no derivative transactions reported for Clene Inc. in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ugwumba Chidozie

(Last)

(First)

(Middle)

609 SW 8TH STREET

SUITE 510

(Street)

BENTONVILLE

72712

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Clene Inc. [ CLNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/13/2026		S		26,105	D	$4.89	682,482	I	By Symbiosis II, LLC
Common Stock	01/14/2026		S		19,621	D	$5.12	662,861	I	By Symbiosis II, LLC
Common Stock	01/15/2026		S		12,563	D	$5.1	650,298	I	By Symbiosis II, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

	/s/ Chidozie Ugwumba	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR